A PYMNTS Company

India: CCI forces changes on Sun Pharma/Ranbaxy deal

By  |  November 16, 2014

The Competition Commission of India will demand changes to the proposed merger between Sun Pharma and Ranbaxy, two pharmaceutical giants set to combine for $3.2 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    CCI chairwoman Ashok Chawla said Friday that the authority has asked the pharmaceutical companies to alter their agreement after the CCI found the deal could harm competition. Specifically, reports say the CCI is concerned the deal would lead to higher generic drug costs.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Chawla said a final ruling will be made by the end of the month, but a spokesperson for Sun said that due to “concerns by the competition regulators,” the deal’s closing could possibly be delayed until after the new year.

    The Sun/Ranbaxy deal has faced particular scrutiny in India, where it would create its largest pharmaceutical company, and the fifth-largest generics manufacturer in the world.

    Full content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.